The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes
Drug Metabolism and Pharmacokinetics · 2021-04 · 37 · 100376
DOI: 10.1016/j.dmpk.2020.100376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2021-04. Verfasst von Yuki Kimura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo,…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Mishima Kaiun Memorial Foundation, Japan Society for the Promotion of Science, Policy-Based Medical Services Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Solute carrier (SLC) 16A11 has been reported as a risk gene for type 2 diabetes (T2D). However, the physiological function of SLC16A11 has not yet been clarified, and the relationship between SLC16A11 and T2D condition remains unclear. Therefore, we performed an association analysis between the SLC16A11 genotype and T2D pathology. The SLC16A11 genotype was determined by direct sequencing in 85 Japanese patients with T2D. The genotypes were analyzed by Mann-Whitney's U test and Chi-square test. Six single nucleotide polymorphisms (SNPs) were detected in the SLC16A11 gene, and five of them formed a haplotype (5SNP haplotype). The 5SNP haplotype carriers had significantly higher fasting plasma glucose (FPG), total cholesterol (T-CHO), and low-density lipoprotein cholesterol (LDL-C) than the noncarriers. The SLC16A11 genotype affected the values of laboratory parameters for T2D, particularly of blood lipids. The function of SLC16A11 may be related to lipid metabolism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, Kita-ku, Sapporo 060-0812, Japan.
- Department of Pharmacy, Hokkaido University Hospital, Kita-14-jo, Nishi-5-chome, Kita-ku, Sapporo 060-8648, Japan.
- Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12-jo, Nishi-6-chome, Kita-ku, Sapporo 060-0812, Japan; Education Research C…
- Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15-jo, Nishi-7-chome, Kita-ku, Sapporo, 060-8638, Japan.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Kita-15-jo, Nishi-7-chome, Kita-ku, Sapporo 060-8638, Japan.
Förderung
- Mishima Kaiun Memorial Foundation
- Japan Society for the Promotion of Science
- Policy-Based Medical Services Foundation
Zitieren
APA
Kimura, Y., Higuchi, I., Kobayashi, M., Furugen, A., Narumi, K., Suzuki, Y., Miyoshi, H., Nakamura, A., Atsumi, T., & Iseki, K. (2021). The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. Drug Metabolism and Pharmacokinetics, 37, 100376. https://doi.org/10.1016/j.dmpk.2020.100376
Vancouver
Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Suzuki Y, et al. The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. Drug Metabolism and Pharmacokinetics. 2021;37:100376. doi:10.1016/j.dmpk.2020.100376
BibTeX
@article{Kimura2021,
author = {Kimura, Yuki and Higuchi, Issei and Kobayashi, Masaki and Furugen, Ayako and Narumi, Katsuya and Suzuki, Yuya and Miyoshi, Hideaki and Nakamura, Akinobu and Atsumi, Tatsuya and Iseki, Ken},
title = {The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes},
journal = {Drug Metabolism and Pharmacokinetics},
year = {2021},
volume = {37},
pages = {100376},
doi = {10.1016/j.dmpk.2020.100376}
}
EUVIMED